T

Tevogen Bio Holdings
D

TVGN

7.92000
USD
-0.50
(-5.94%)
مغلق
حجم التداول
1,464
الربح لكل سهم
-10
العائد الربحي
-
P/E
-1
حجم السوق
33,165,040
المقالات
المزيد

العنوان: Tevogen Bio Holdings Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.